HomeOncologyBreast CancerFDA approves Ibrance for postmenopausal women with metastatic breast cancer

FDA approves Ibrance for postmenopausal women with metastatic breast cancer

On February 3, the U.S. Food and Drug Administration (FDA) approved Ibrance (palbociclib) to treat advanced metastatic breast cancer. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

NP taking pregnant woman's blood pressure

AHA: It’s Safe to Treat High Blood Pressure During Pregnancy

High blood pressure during pregnancy can present significant risks to mother and child, but practitioners have sometimes be hesitant to prescribe blood pressure medication...